
News • Pediatric leukemia
‘Turbocharged Artificial Intelligence’ could personalize combination therapy
A team of UCLA bioengineers has demonstrated that its technology may go a long way toward overcoming the challenges of treatment for acute lymphoblastic leukemia, among the most common types of cancer in children, and has the potential to help doctors personalize drug doses.






















